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Comment on: Silencing histone deacetylase 2
using small hairpin RNA induces regression of
fibrotic plaque in a rat model of Peyronie’s
disease. KD Kwon, MJ Choi, JM Park, KM Song,
MH Kwon, D Batbold, GN Yin, WJ Kim, JK Ryu,
JK Suh. BJU Int 2014;114:926.
Over the past decade we have begun to understand
the molecular and genetic underpinnings of
Peyronie’s disease (PD). We now know that the
transforming growth factor (TGF)-β signaling
pathway is one of the major contributors to aber-
rant ﬁbrosis in PD, and are beginning to under-
stand that other pathways, including the Wnt/β-
catenin and mitogen-activated protein kinase
pathways may also be involved [1]. Our under-
standing of genetic factors that predispose to
superﬁcial ﬁbrotic disorders is growing as well,
with work over the past decade linking WNT
pathway and human leukocyte antigen genes, as
well as Dupuytren contracture 1 to these condi-
tions [2–4].
More recently, epigenetic regulation of gene
expression has become a focus for several groups
studying the etiologies of aberrant ﬁbrosis.
Histone deacetylases (HDACs) can regulate a
gene’s expression by modifying the ability of tran-
scriptional machinery to access the gene’s pro-
moter. In terms of clinical relevance, HDACs have
been implicated in the pathogenesis of ﬁbrotic dis-
orders of the heart, lungs, liver, bladder and
kidneys, and inhibition of HDACs can repress
TGF-β-mediated signaling [5–7]. In 2009, Ryu
et al. found that knockdown of HDAC2 using
RNA interference (RNAi) decreased the expres-
sion of proﬁbrotic factors in PD ﬁbroblasts after
stimulation with TGF-β [8]. More importantly,
the conversion of ﬁbroblasts into myoﬁbroblasts,
the causal cell type in PD ﬁbrosis, was blocked
when HDAC2 was knocked down. Signaling
through the TGF-β pathway requires SMAD pro-
teins, which shuttle between the cytoplasm and
nucleus and activate gene expression when the
pathway is activated. Ryu et al. [8] also observed
reduced phosphorylation and nuclear migration of
SMAD2/3 after HDAC2 knockdown, supporting
repressed activation of the TGF-β pathway with
reduced HDAC2 activity. While this work pro-
vided evidence that HDACs may be involved in
ﬁbrosis in vitro, it did not address the impact of
HDAC inhibition in vivo.
Building on this work, Kwon and colleagues
investigated the impact of RNAi, using a short
hairpin RNA (shRNA) against HDAC2 on PD
plaque size in a rat model of PD, demonstrating
plaque regression in rats treated with anti-
HDAC2 shRNA [9]. In order to evaluate HDAC2
knockdown in vivo, the authors performed RNAi
by incorporating an anti-HDAC2shRNA into an
adenoviral vector, which can infect living cells.
Four groups of six rats were used, and PD was
induced in three of the four groups using ﬁbrin
and thrombin injections into the tunica albuginea.
Fifteen days after this injection, the adenoviral
shRNA constructs were injected directly into PD
plaques. The test groups included (i) no PD; (ii)
PD without treatment; (iii) treatment with
scramble shRNA (control) vector; and (iv) treat-
ment with anti-HDAC2 shRNA vector. Fifteen
days after injection of adenoviral shRNA con-
structs (30 days after ﬁbrin and thrombinSeptember 2015
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injections), rats were sacriﬁced and their penises
histologically evaluated. First, the authors demon-
strated that thrombin and ﬁbrin injections resulted
in ﬁbrotic plaque formation. Next, PD plaque size
in each group was found to be signiﬁcantly smaller
only in rats treated with anti-HDAC2 shRNA
when compared with controls. Treatment with
anti-HDAC2 shRNA also resulted in decreased
inﬂammatory cell inﬁltration and transnuclear
expression of phosphorylated Smad3, supporting
inhibition of TGF-β pathway signaling as the
mechanism for reduced PD plaque size.
The authors further evaluated the impact of
HDAC2 silencing in human PD plaque-derived
ﬁbroblasts. Using small interfering RNA (siRNA),
another form of RNAi, inhibition of myoﬁbroblast
differentiation in anti-HDAC2 siRNA-treated
ﬁbroblasts was observed. To further demonstrate
how inhibition of HDAC2 function limits ﬁbrosis
in vitro through the TGF-β pathway, the authors
evaluated hydroxyproline production in these PD
plaque-derived ﬁbroblasts. Hydroxyproline is an
integral stabilizing component of collagen and a
relatively speciﬁc marker of collagen content.
PD plaque-derived ﬁbroblasts treated with
TGF-β1 showed signiﬁcantly elevated levels of
hydroxyproline, whereas cells treated with both
TGF-β1 and anti-HDAC2 siRNA did not, further
supporting a role for HDAC2 in mediating TGF-β
signaling and subsequent ﬁbrosis. While the pres-
ence of myoﬁbroblasts is important in PD patho-
genesis, the lack of apoptosis in thesemyoﬁboblasts
at the completion ofwoundhealing is a key factor in
aberrant, persistent ﬁbrosis in PD. The authors
found that knockdown of HDAC2 blocked cell
cycle entry and induced apoptosis in PD plaque-
derived ﬁbroblasts, directly demonstrating that an
active TGF-β pathway can result in myoﬁbroblast
persistence.
Taken together, these ﬁndings support involve-
ment of HDAC2 in modulating TGF-β signaling,
myoﬁbroblast persistence, and penile ﬁbrosis, and
highlight another potential target for small-
molecule PD therapies. While additional work
deﬁning the precise mechanisms by which
HDACs regulate TGF-β signaling is necessary,
the impact on disease is rapidly becoming clear. An
important caveat is that current HDAC inhibitors
are nonspeciﬁc and block the actions of several
HDACs; this may limit their utility as systemic
treatments. However, localized therapy in the
form of penile injections may be a viable treatment
option for PD and other superﬁcial, localized
ﬁbrosing disorders in the future. Studies evaluat-
ing the impact of HDAC inhibitors in PD over
longer durations are needed, and the impact on
penile curvature and other clinical parameters will
need to be determined. Nevertheless, these ﬁnd-
ings speak to our growing understanding of the
breadth of factors that are involved in aberrant
ﬁbrosis and our expanding ability to treat these
conditions.
Alexander W. Pastuszak, MD, PhD
References
1 Huang C, Ogawa R. Fibroproliferative disorders and their
mechanobiology. Connect Tissue Res 2012;53:187–96.
2 Dolmans GH, Werker PM, Hennies HC, Furniss D, Festen EA,
Franke L, Becker K, van der Vlies P, Wolffenbuttel BH,
Tinschert S, Toliat MR, Nothnagel M, Franke A, Klopp N,
Wichmann HE, Nürnberg P, Giele H, Ophoff RA, Wijmenga
C; Dutch Dupuytren Study Group; German Dupuytren Study
Group; LifeLines Cohort Study; BSSH-GODD Consortium.
Wnt signaling and Dupuytren’s disease. N Engl J Med
2011;365:307–17.
3 Nachtsheim DA, Rearden A. Peyronie’s disease is associated
with an HLA class II antigen, HLA-DQ5, implying an autoim-
mune etiology. J Urol 1996;156:1330–4.
4 Rompel R, Mueller-Eckhardt G, Schroeder-Printzen I,
Weidner W. HLA antigens in Peyronie’s disease. Urol Int
1994;52:34–7.
5 Pang M, Zhuang S. Histone deacetylase: A potential therapeutic
target for ﬁbrotic disorders. J Pharmacol Exp Ther
2010;335:266–72.
6 Hodges SJ, Yoo JJ, Mishra N, Atala A. The effect of epigenetic
therapy on congenital neurogenic bladders—A pilot study.
Urology 2010;75:868–72.
7 Qin L, Han YP. Epigenetic repression of matrix
metalloproteinases in myoﬁbroblastic hepatic stellate cells
through histone deacetylases 4: Implication in tissue ﬁbrosis. Am
J Pathol 2010;177:1915–28.
8 Ryu JK, Kim WJ, Choi MJ, et al. Inhibition of histone
deacetylase 2 mitigates proﬁbrotic TGF-beta1 responses in
ﬁbroblasts derived from Peyronie’s plaque. Asian J Androl
2013;15:640–5.
9 Kwon KD, Choi MJ, Park JM, et al. Silencing histone
deacetylase 2 using small hairpin RNA induces regression of
ﬁbrotic plaque in a rat model of Peyronie’s disease. BJU Int
2014;114:926–36.
Comment on: Novel therapeutic approach for
neurogenic erectile dysfunction: effect of
neurotrophic tyrosine kinase receptor type 1
monoclonal antibody. G Lin, H Li, X Zhang, J
Wang, U Zaid, MT Sanford, V Tu, A Wu, L
Wang, F Tian, H Kotanides, V Krishnan, G
Wang, H Ning, L Banie, CS Lin, GG Deng, TF
Lue. Eur Urol 2015 Apr;67(4):716–26.
Erectile dysfunction (ED) after nerve-sparing
radical prostatectomy (NSRP) represents one of
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the major challenges for practicing urologists [1].
Often, ED manifests immediately after surgery,
owing to the inevitable, but often temporary
damage to the cavernous nerves during surgery.
This damage results from traction, crushing, and
thermal injury to the neurovascular bundles, pro-
moting Wallerian nerve degeneration and result-
ing in penile denervation. As a result, both daily
and nocturnal erections are reduced, and a persis-
tent state of cavernous hypoxia exists.
In vitro and in vivo data support the concept that
penile hypoxia results in collagen accumulation,
smooth muscle apoptosis, and ﬁbrosis, which may
lead to irreversible ED [2]. The increasing atten-
tion on quality of life in surgically treated patients
has promoted the concept of a therapy that can
counteract the deleterious effects of NSRP on EF.
The concept of penile rehabilitation, ﬁrst sug-
gested by Montorsi et al. in 1997, is based on the
use of therapies that can preserve EF through
improvement of cavernosal oxygenation so as to
maintain proper endothelial cell function and
prevent smooth muscle ﬁbrosis [3]. So-called
penile rehabilitation therapy, typically involving
routine dosing of phosphodiesterase-5 inhibitors
(PDE5i), is in wide spread use for penile rehabili-
tation in the absence of solid clinical evidence [1].
Indeed, although preclinical studies using cavern-
ous nerve injury in animal models have demon-
strated that PDE5i can promote erectile function
recovery, most clinical trials have not shown this to
be the case in humans [2,4]. Consequently, both
clinical and translational researchers are continu-
ing to look for new treatments to prevent perma-
nent ED following NSRP.
The role of sympathetic neurotransmission in
ED is increasingly relevant in sexual medicine,
particularly in the setting of penile rehabilitation
after RP. Several authors have suggested that
sympathetic hyper-innervation may cause exces-
sive contraction of penile smooth muscle, result-
ing in ED. Hsieh et al. showed that, following
injury to the cavernous nerves, regenerated sym-
pathetic ﬁbers are more numerous than regener-
ated parasympathetic ﬁbers [5]. Martinez-
Salamanca et al. brilliantly demonstrated that
cavernosal smooth muscle strips derived from
human corporal tissue following RP were more
responsive to adrenergic induced contraction and
less responsive to NO-induced relaxation when
compared with corporal tissue from men who
had not had RP [6].
Nerve growth factor (NGF) is a small, secreted
protein important for growth, maintenance, and
survival of nerve cells, particularly sympathetic and
sensory neurons. NGF binds to at least two classes
of receptors: the p75 LNGFR (for “low-afﬁnity
nerve growth factor receptor”) neurotrophin
receptor (p75(NTR)) and TrkA, a transmembrane
tyrosine kinase [7,8]. Based on evidence that
NGF/TrkA signaling regulates sympathetic
neuron growth cone formation, Lin et al. [9]
hypothesized that a speciﬁc TrkA monoclonal
antibody (TrkA-mAb) might block regeneration of
peripheral sympathetic neurons after cavernous
nerve injury (CNI), inhibiting the aberrant sym-
pathetic neuritogenesis to corporal cavernosal
smooth muscle. In the present study, the authors
reported, indeed, that TrkA-mAb treatment pro-
motes the recovery of normal sexual behaviour and
erectile function after CNI in rats, and that the
balance between expression of tyrosine
hydroxylase (a marker for sympathetic neurons)
and neuronal nitric oxide (nNOS; expressed in
nonadrenergic/noncholinergic [NANC] parasym-
pathetic ﬁbers) was restored. Most importantly,
the authors showed that TrkA antibody treatment
was able to prevent ﬁbrosis and smooth muscle
loss in the corpora cavernosa [9].
While this study has heavily contributed to the
recent use of monoclonal antibodies in modulating
endogenous neuroregeneration, it is not free from
limitations. As already pointed out by Weyne and
coauthors [10], it is not clear whether the reduc-
tion in penile ﬁbrosis is due to improved oxygen-
ation of these tissues via activity of regenerated
NANC ﬁbers or through a direct inhibitory effect
on ﬁbrotic pathways under sympathetic control,
such as RhoA/ROCK signaling. Furthermore,
owing to the short duration of evaluation (6
weeks), it is unclear whether this kind of treatment
promotes only a more rapid EF recovery rather
than a real beneﬁt in terms of EF recovery rate.
Indeed it is possible that a certain proportion of
healthy animals after CNI could have recovered
EF within a longer timeframe, as previously
reported by Kim et al. [11]
In addition, from a translational point of view,
the effect of systemic administration of TrkA-mAb
on prostate cancer growth and on sympathetic
innervation throughout the body could represent a
very important issue that may limit its use in the
clinical setting.
Fabio Castiglione, MD
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Male Clinical Research
Comment on: Extracorporeal shockwave
therapy in the treatment of erectile dysfunc-
tion: A prospective, randomized, double-
blinded, placebo controlled study. CH Yee, ES
Chan, SS Hou, CF Ng. Int J Urol 2014;21:
1041–5.
Currently 52% of men between 40 and 70 years
have some degree of erectile dysfunction (ED)
and annually 26 out of every 1,000 men are
diagnosed with ED. Since the late nineties,
phosphodiesterase-5 (PDE5) inhibitors have
become the ﬁrst-line therapeutic option for ED,
because of their high efﬁciency and low therapeutic
invasiveness. However, several important deﬁcien-
cies must be considered: (i) PDE5I have adverse
effects rates up to 16%; (ii) PDE5 inhibitors are
most commonly used on demand, reducing spon-
taneity in the sexual relationship; (iii) PDE5 inhibi-
tors cannot be used by men taking nitrates and
those with high-risk cardiac problems; (iv) high
rates of discontinuation. Furthermore, the use of
these drugs does not “cure”EDbecause they do not
alter the pathophysiology of the disease perma-
nently. Alternative treatment options (e.g.,
intracavernosal vasoactive drugs, penile prosthet-
ics) are more invasive and basic and not acceptable
to all patients.
As one of the pathophysiologic factors in ED is
the lack of arterial supply for the cavernous bodies,
the possibility of using low-intensity extracorporeal
shockwave therapy (LIEST) in the treatment ofED
seems to be attractive. This idea is supported by the
use of LIEST in other diseases such as orthopedic
disorders, wound healing, peripheral neuropathy,
etc. LIEST consists of shock waves that propagates
and reaches the tissues causing a mechanical
microtrauma called “shear stress”. This process
triggers a response of the tissue with release of
proangiogenic cytokines (e.g., nitric oxide
synthase, vascular endothelial growth factor and
ﬁbroblast growth factor) stimulating issue
neovascularization.
Yee et al. conducted a double-blind placebo ran-
domized study with 58 patients divided into two
groups. Group 1 consisted of 30 patients who
underwent LIEST therapy, whereas Group 2 con-
sisted of 28 patients who underwent a procedure
that simulated LIEST therapy (sham group).
Overall, there was no difference between groups
with respect to the International Index of Erectile
Function (IIEF) questionnaire and Erection Hard-
ness Score. However, subgroup analyses revealed
that the questionnaire outcomes of the patients
with severe ED were signiﬁcantly better among
patients who underwent LIEST therapy (IIEF-ED
domain improvement: 10.1 ± 4.1 in LIEST group
vs. 3.2 ± 3.3; P = 0.003 in the sham therapy group).
There was no report of any treatment-related
adverse effects.
Despite evidence to demonstrate good efﬁcacy
and safety of LIEST to treat ED, the evidence
level of the previously published studies is low.
The technical protocol currently used is empiri-
cal and derived from the use of shockwave
therapy in other diseases; as such it may not be
the optimal treatment regimen. Furthermore, the
characteristics of ED patients who would be ideal
candidates for this therapy are not clear. New
basic research studies should explore the effects
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of LIEST on cellular level with particularly
regards the duration of neovascularization. In
summary, if LIEST is to have a role in ED man-
agement many more clinical and basic research
studies will be required.
David Jacques Cohen, MD
Comment on: Can sexual intercourse be an
alternative therapy for distal ureteral stones?
A prospective, randomized, controlled study.
OGDoluoglu, ADemirbas,MFKilinc,TKarakan,
M Kabar, S Bozkurt, B Resorlu. Urology
2015;86(1):19–24.
Urinary tract lithiasis is a highly prevalent disease,
which annually has high costs for the healthcare
system. Alpha blockers are recommended as ﬁrst-
line therapy for distal ureteral stones smaller than
6 mm, based on the premise that this region is rich
in adrenergic receptors. Several clinical studies
have shown that the use of alpha blockers facili-
tates the passage of distal ureteral stones and
decrease the need of analgesic medications. In
addition, many animal studies have shown that the
distal ureteral region is also rich in nitric oxide
(NO) receptors and activation of these receptors
also promotes ureteral relaxation. Based on these
factors Doluoglu et al. postulated that during
increases in NO may occur in the distal third of
the ureter during penile erection and intercourse;
this would have the theoretical effect of enhancing
stone passage.
In this prospective randomized study, patients
with distal ureteral stones up to 6 mm were
divided into three groups: Group 1: patients were
recommended to have sex at least thrice a week;
Group 2 patients were recommended to use
alpha blockers and not to have sexual intercourse;
Group 3 patients were recommended to use
general clinical measures such as hydration and
analgesics (control group). Two weeks later, 26 of
31 patients (83.9%) in the sexual intercourse
group, 10 of 21 patients (47.6%) in the alpha
blocker group, and 8 of 23 (34.8%) patients in
the control group passed their stones (P = 0.001).
The mean stone expulsion time was 10 days in
group 1, 16.6 days in group 2, and 18 days in
group 3 (P = 0.0001). The analgesic needs were
found to be signiﬁcantly less in the treatment
groups compared to controls (P = 0.001).
This study opens new horizons to be investi-
gated, including the theoretical consideration that
potentiation of the NO/cGMP pathway (possibly
using phosphodiesterase inhibitors) may enhance
the treatment of ureteral stones. However, several
questions must be elucidated. Whether similar
results may be produced with NO/cGMP
activiation vs. actual intercourse is not clear.
Whether similar mechanisms are active in women
is another consideration for future research. The
exact mechanism by which sexual stimulation acts
to release NO in penile tissue is very well known;
however, how/whether this happens in the distal
ureter with sexual arousal must be explored.
Whether physical exercises would replicate these
ﬁndings is yet another possible avenue for future
research. This study establishes an association, but
the causative factors remain to be elucidated.
Regardless of mechanism of action, simple and
cheap behavioral measures such as this should be
encouraged and implemented in management of
urinary stone diseases.
David Jacques Cohen, MD
Male Mental Health
Comment on: Self-efficacy as a relevant con-
struct in understanding sexual response and
dysfunction. DL Rowland, BA Adamski, CJ Neil,
AM Myers, AL Burnett. J Sex Marital Ther
2015;41:60–71.
Self-efﬁcacy relates to one’s perceived ability to be
successful at a given task. Consequently, a sense of
self-efﬁcacy inﬂuences our cognitive and emo-
tional reactions to many situations. Self-efﬁcacy is
widely recognized as a key construct inﬂuencing
general psychological well-being, and to a certain
degree, it is believed to impact human sexual func-
tioning. Low self-efﬁcacy has been described in
the context of premature ejaculation, but its inﬂu-
ence is likely to occur in all areas of sexual func-
tioning, particularly in those involving some level
of performance demand.
Sexual situations may be appraised differently—
positively or negatively—depending on a man’s per-
ception about being capable of achieving a certain
degree of sexual performance. This appraisal
impacts male sexual response; negative appraisals
are often related to erectile difﬁculties or to the
underestimation of real erection levels. As a unify-
ing construct encompassing cognitive and emo-
tional components, but also a behavioral
dimension, the sense of self-efﬁcacy may be crucial
to how men anticipate and react (physically and
emotionally) to sexual situations, acting as a
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vulnerability factor for male sexual difﬁculties, par-
ticularly in sexually demanding cases.
In the present study, the authors have addressed
this issue not only by developing a self-report
measure aimed at assessing sexual self-efﬁcacy for
men with erectile dysfunction (ED), but also by
testing whether this new measure relates to other
markers characterizing men with sexual dysfunc-
tion. The sample was comprised of 74 hetero-
sexual men (60 with ED and 14 controls;
Mage = 54.6, standard deviation = 12.9), who had
been clients of the James Buchanan Brady
Urological Institute at The Johns Hopkins
Medical Institute. All men were in a partnered
sexual relationship for at least 6 months. Findings
revealed that sexual self-efﬁcacy discriminated
between men with ED and controls. In particular,
among men with ED, those attributing a high
importance to sex showed the lowest self-efﬁcacy.
This suggests that men combining high expecta-
tions about sex and a low sense of sexual conﬁ-
dence are at risk of sexual difﬁculties. Also, data
showed that the severity of sexual difﬁculties was
negatively related to sexual self-efﬁcacy (i.e., the
higher the severity, the lower the sexual self-
efﬁcacy). Finally, ﬁndings further revealed that low
sexual self-efﬁcacy negatively impacts men’s emo-
tional response during partnered sex.
These ﬁndings demonstate that a complex array
of psychological dispositions and expectations
interact with the biological underpinnings of male
erectile response, shaping howmen react physically
and affectively during sexual encounters. Sexual
self-efﬁcacy is expected to serve as a key clinical
target, both for assessment and treatment. Enhanc-
ing a man’s sexual self-efﬁcacy—and possibly adjust-
ing his sexual expectations—would likely increase the
chances of achieving a desired treatment outcome,
including improving genital response, but also
emotional, relational, and sexual satisfaction.
Joana Carvalho, PhD
LGBT Studies
Comment on: Women who have sex with
women living in low- and middle-income
countries: A systematic review of sexual health
and risk behaviors. SA Tat, JM Marrazzo, SM
Graham. LGBT Health 2015;2:91–104.
A lack of research inclusive of lesbian, gay, and
bisexual (LGB) persons is not a new notion.Within
the sexual health literature for LGB persons, a
further lack of inclusiveness of women is not unlike
health and medical sciences research more broadly.
So it is perhaps no surprise there is even less
research on lesbian and bisexual women in low- and
middle-income countries. A broad, systematic
review provided by Tat, Marrazzo, and Graham has
shed light on this issue and what we do know.
The systematic review considers the sexual
health and associated risk behaviors forwomenwho
have sexwithwomen in such countries.Using three
primary and relevant search databases, the authors
identiﬁed just 56 articles since 1980meeting appro-
priate review criteria. The synthesis provided high-
lights of the risk behaviors associated with negative
sexual health outcomes, namely having sex with
men, sex work, and injection drug use, which were
the most commonly noted behaviors across the
studies identiﬁed. Many other articles identiﬁed
barriers to positive sexual health outcomes includ-
ing stigma, discrimination, and violence.
The review, while limited by the search of only
three databases (PubMed, Embase, and CINAHL)
and noninclusive of gray literature (e.g., govern-
mental and nongovernmental organization [NGO]
reports), provides two key points for practitioners
and researchers in sexual medicine: (i) exposure to
negative sexual health outcomes, including HIV
and other STIs, for WSW in low- and middle-
income countries is a real and pressing issue (e.g.,
self-identifying as a lesbian does not preclude one
from such issues) and is situated in a unique cultural
and economic context; and (ii) there is a severe need
for more research that allows more generalizable
ﬁndings to support the development of funded
resources and interventions for these women, par-
ticularly through the inclusion of identity questions
in standardized longitudinal government and
NGO studies. Finally, the review serves as an excel-
lent source of information providing summaries
(see Tables 1 and 2) of the literature found which
may prove useful for others looking to further
understand and continue this important work.
Christopher Fisher, PhD
Comment on: Cancer and Lesbian, Gay,
Bisexual, Transgender/Transsexual, and
Queer/Questioning (LGBTQ)populations.GP
Quinn, JA Sanchez, SK Sutton, ST Vadaparampil,
GT Nguyen, BL Green, PA Kanetsky, MB
Schabath. CA Cancer J Clin 2015 Jul 17. doi:
10.3322/caac.21288. [Epub ahead of print].
Lesbian, gay, bisexual, transgender/transsexual,
and queer/questioning (LGBTQ) individuals face
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poorer health outcomes than the general popula-
tion; lack of knowledge about their speciﬁc health-
care needs, particularly with respect to chronic
diseases, is a contributory factor. The prevention,
early detection, diagnosis, treatment, survivorship,
and end-of-life care for LGBTQ populations with
respect to seven speciﬁc cancer types (anal, breast,
cervical, colo-rectal, lung, endometrial, prostate)
were described by Quinn et al. [1] LGBTQ people
are more likely to remain silent about important
health issues, at least in part because of fear of
stigmatization; many healthcare professionals lack
knowledge of their speciﬁc healthcare needs, and
may have negative attitudes towards them. They
identify barriers to care experienced by trans
people and suggest strategies for improving access.
Human papilloma virus (HPV) as a risk factor in
the development of anal and cervical cancer in
transgender people, both sexually active and inac-
tive, is discussed; consistent male condom use and
immunization with quadrivalent HPV vaccine are
recommended as preventive measures. An impor-
tant omission is a discussion of endometrial cancer
risk in trans men with a uterus who maintain long-
term amenorrhea through the use of testosterone
and other drugs, but, overall, this review is impor-
tant reading for all clinicians working in Sexual
Medicine and Trans Healthcare.
John Dean, MBBS, FRCGP, FECSM
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Comment on: Prevalence of human
papillomavirus infection in a clinic sample of
transsexuals in Italy. G Loverro, E Di Naro, AM
Caringella, AL De Robertis, D Loconsole, M
Chironna. Sex Transm Infect 2015 Jul 22. ISSN:
1472-3263 (Electronic).
Human papilloma virus (HPV) infection is an
important risk factor for the development of some
cancers in transgender people, Loverro et al. [1]
report the prevalence of detectable HPV DNA in a
clinic sample of 35 trans people attending a Gender
Clinic inBari, Italy.HPVDNAwas detected in 14of
35 patients (40.0%); 13/34 in anal samples, 2/22 in
vaginal samples, and 1/12 in penile samples. Onco-
genic HPV genotypes have been detected in 93% of
HPV-positive subjects. More than one-third was
infected with at least one of the four vaccine-
preventable genotypes, 6, 11, 16, and 18. On the
basis of their ﬁnding, the authors recommend HPV
vaccination for younger transgender people.
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Comment on: Five new cases of breast cancer
in transsexual persons. L Gooren, M Bowers, P
Lips, IR Konings. Andrologia 2015 Jan 22. ISSN:
1439-0272 (Electronic).
Gooren et al. report ﬁve cases of breast cancer,
three in trans men and two in trans women [1].
They comment that in the general population the
incidence of breast cancer increases with age and
with duration of exposure to sex hormones but, in
these ﬁve cases, tumours occurred at a relatively
young age (4/5 under 50 years) and mostly after a
relatively short period of cross-sex hormone treat-
ment (4/5 for ≤10 years). Overall, occurrence of
breast cancer was rare. The World Professional Asso-
ciation for Transgender Health Standards of Care,
version 7, recommend that clinicians should
consult their national evidence-based guidelines
and discuss screening with their patients in light of
the effects of hormone therapy on their baseline
risk. However, in the absence of large-scale pro-
spective studies, there is inadequate evidence to
determine the appropriateness and frequency of
mammography screening. Typically, trans women
who have received hormone therapy are offered
screening from the age of 50 years and trans men
who have had chest reconstruction are not. It
should be noted that four of the ﬁve the cancers
reported by Gooren et al. were diagnosed before
the age at which screening usually commences.
Health professionals working with trans people
may consider offering them “breast awareness”
advice at the initiation of hormone therapy and
encourage them to report any breast changes.
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Comment on: A review of the physical and
metabolic effects of cross-sex hormonal
therapy in the treatment of gender dysphoria.
LJ Seal. Ann Clin Biochem 2015. Published online
before print May 1, 2015.
In Annals of Clinical Biochemistry, Seal [1] has
authored a comprehensive review of the metabolic
and hormonal effects of cross-gender sex steroid
therapy, and describes the regimens used in a state-
funded Gender Identity Clinic in England. It pro-
vides a useful overview of the risks, beneﬁts, and
limitations of contemporary treatment in Europe;
it also reveals the paucity of contemporary out-
comes research in this ﬁeld, as the review has to rely
upon some studies conducted in the 1980s and
1990s. A good accompaniment to Seal’s review is a
review by Gooren et al. [2] in Andrologia that
explores the impact of genetic factors, both
autosomal and sex-linked, on the desired and unde-
sired effects of cross-sex hormone therapy. The
authors point out that differences in genome (pres-
ence of a Y chromosome, “dosage” of X chromo-
some genes, etc.) result in differences in gonadal
andnongonadal tissues, and their response to cross-
sex steroids, which may explain the persistence of
differences in natal sex-determined cardiovascular
risk in trans people treated with cross-sex steroids.
For example, the SRY gene, located on the Y chro-
mosome, not only determines pre-natal testicular
development, but also modulates tyrosine metabo-
lism (part of the noradrenaline synthesis pathway)
throughout life and may, as a consequence, predis-
pose people with that gene (cis men or trans
women) to develop hypertension. Other examples,
and differences in bone and immunological
response, are also described.
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